Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-14

Study Completion Date

2024-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part A (single-agent dose escalation) and Part B (single-agent expansion cohorts).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of PLX108-01 in Patients With Solid Tumors

NCT01004861

Solid Tumor

COMPLETED PHASE1

A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

NCT02646852

Tumors Neoplasms Cancer

COMPLETED PHASE1

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075

Solid Tumor Lymphoma

COMPLETED PHASE1

Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01300468

Solid Tumour

COMPLETED PHASE1

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530

Solid Tumor Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations Tenosynovial Giant Cell Tumor

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part A (single-agent dose escalation) and Part B (single-agent expansion cohorts).

For Part A dose-escalation, patients will be enrolled in cohorts of 3 to 6 patients to each dose level. A new dose level cannot open to accrual until toxicity has been determined in the preceding dose level (i.e. all patients have completed their first cycle of therapy and data for all patients in that dose level have been reviewed at a safety cohort review meeting). Six patients will be treated at the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D). If required, the MTD cohort may be expanded by an additional 10 patients for further toxicity and response assessment. The MTD cohort expansion may be restricted to B-cell lymphoma or advanced solid tumours to ensure there is proper distribution during dose escalation.

For Part B (single agent expansion cohorts), two expansion cohorts (N=20 each) will be opened to determine the preliminary clinical activity of PCLX-001 at the RP2D:

* Expansion Cohort A: Participants with advanced solid malignancies showing preclinical sensitivity or molecular markers of sensitivity to PCLX-001. This includes breast, nonsmall cell lung (NSCLC), small-cell lung (SCLC), colorectal (CRC), and bladder cancers
* Expansion Cohort B: Participants with relapsed/refractory (R/R) B-cell lymphoma: diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and Burkitt lymphoma. Transformed large B-cell lymphoma will also be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

B-cell Non Hodgkin Lymphoma Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

For Part A dose-escalation, patients will be enrolled in cohorts of 3 to 6 patients to each dose level. Six patients will be treated at the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCLX-001 intervention 20mg

Cohort 1: Participants were administered 20mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 20mg

Intervention Type DRUG

20mg daily oral pills

PCLX-001 intervention 40mg

Cohort 2: Participants were administered 40mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 40mg

Intervention Type DRUG

40mg daily oral pills

PCLX-001 intervention 70mg

Cohort 3: Participants were administered 70mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 70mg

Intervention Type DRUG

70mg daily oral pills

PCLX-001 intervention 100mg

Cohort 4: Participants were administered 100mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 100mg

Intervention Type DRUG

100mg daily oral pills

PCLX-001 intervention 140mg

Cohort 5: Participants were administered 140mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 140mg

Intervention Type DRUG

140mg daily oral pills

PCLX-001 intervention 210mg

Cohort 6: Participants were administered 210mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 210mg

Intervention Type DRUG

210mg daily oral pills

PCLX-001 intervention 280mg

Cohort 7: Participants were administered 280mg of PCLX-001 orally as continuous daily dosing on a 28-day cycle.

Group Type EXPERIMENTAL

PCLX-001 - 280mg

Intervention Type DRUG

280mg daily oral pills

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCLX-001 - 20mg

20mg daily oral pills

Intervention Type DRUG

PCLX-001 - 40mg

40mg daily oral pills

Intervention Type DRUG

PCLX-001 - 70mg

70mg daily oral pills

Intervention Type DRUG

PCLX-001 - 100mg

100mg daily oral pills

Intervention Type DRUG

PCLX-001 - 140mg

140mg daily oral pills

Intervention Type DRUG

PCLX-001 - 210mg

210mg daily oral pills

Intervention Type DRUG

PCLX-001 - 280mg

280mg daily oral pills

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

zelenirstat zelenirstat zelenirstat zelenirstat zelenirstat zelenirstat zelenirstat

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained before any study-specific procedures are performed.
2. Male or female patients aged ≥ 18 years
3. Dose Escalation

1. Participants with histologically-confirmed advanced solid tumor who have failed at least one prior therapy and/or are not eligible for therapies expected to provide clinical benefit.
2. Histologically-confirmed B-cell lymphomas that are expected to express CD20 including DLBCL, HGBL, FL (grades 1 to 3b), MCL, and Burkitt lymphoma who have failed at least two prior therapies and/or are not eligible for therapies expected to provide clinical benefit (including autologous stem cell transplantation). Transformed large B-cell lymphoma patients are eligible. FL patients should meet criteria for requiring treatment.

Dose Expansion Cohort A: Participants with histologically-confirmed advanced breast, NSCLC, SCLC, colorectal, and bladder cancers who have failed at least one prior therapy and/or are not eligible for therapies expected to provide clinical benefit.

Cohort B: Participants with histologically-confirmed R/R B-cell lymphomas that are expected to express CD20 including DLBCL, HGBL, FL (grades 1-3a), FL (grade 3b), MCL, and Burkitt lymphoma who have failed at least two prior therapies and/or are not eligible for therapies expected to provide clinical benefit. Transformed large B-cell lymphoma patients are eligible. FL patients should meet criteria for requiring treatment.
4. Patients must have evaluable or measurable disease.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
6. Life expectancy of at least 12 weeks
7. Patients must have adequate bone marrow, liver, kidney and cardiac function.
8. Patients must have adequate coagulation.
9. Women of childbearing potential must have a negative pregnancy test.
10. Women of childbearing potential and fertile men must agree to use adequate contraception when sexually active from signing of the informed consent form for the full study until at least 6 months after the last study drug administration.

Exclusion Criteria

1. Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.
2. History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class \> II, unstable angina (angina symptoms at rest), new-onset angina (within the past 6 months before study entry), myocardial infarction within the past 6 months before study entry, or uncontrolled cardiac arrhythmias.
3. Uncontrolled arterial hypertension despite optimal medical management.
4. Moderate or severe hepatic impairment.
5. Patients with known human immunodeficiency virus (HIV) infection.
6. Patients who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.
7. Infections not responding to therapy or active clinically serious infections.
8. Symptomatic metastatic brain or meningeal tumors unless the patient is \> 3 months from definitive therapy, has a stable imaging study and is clinically stable. Patients with asymptomatic brain metastases must not be on steroid therapy.
9. Current or past history of central nervous system (CNS) lymphoma.
10. Uncontrolled seizure disorder requiring therapy.
11. History of organ allograft transplantation or autologous stem cell transplantation ≤ 3 months prior to the first dose of study drug. Patients who received prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to study drug administration.
12. Evidence or history of bleeding disorder within 4 weeks before the first dose of study drug.
13. Serious, non-healing wound, ulcer, or bone fracture.
14. Any malabsorption condition.
15. Breastfeeding. Female patients must not breastfeed during treatment and until 4 months after last study drug administration.
16. Treatment with systemic steroids (prednisone dose ≥10 mg/day or equivalent dose).
17. Acute toxic effects of previous anticancer chemotherapy or immunotherapy that have not yet stabilized or if significant post-treatment toxicities have been observed.
18. Radiotherapy for target lesions during study or within 3 weeks before the first dose of study drug.
19. Major surgery or significant trauma within 4 weeks before the first dose of study drug.
20. Concomitant participation in another clinical study with investigational medicinal product(s).
21. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
22. Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug. Strong CYP3A4 inhibitors and inducers are prohibited during the study and until the active follow up visit.
23. Clinically relevant findings in the ECG.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No